Drugs / Pazufloxacin
Pazufloxacin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03696342 | Oct 2018 → Mar 2020 | bacterial conjunctivitis | Laboratorios Sophia S.A de C.V. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pazufloxacin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03696342 ↗ |
| Known as | Pazufloxacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL240163 ↗ |
| Known as | Pazufloxacino | ChEMBL registry synonym — accepted as the source's own label CHEMBL240163 ↗ |
| Known as | T-3761 | ChEMBL registry synonym — accepted as the source's own label CHEMBL240163 ↗ |
| Modality | Small molecule | — CHEMBL240163 ↗ |
| Route | Topical | “Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic” NCT03696342 ↗ |